Candriam S.C.A. Sells 11,576 Shares of Exact Sciences Corporation $EXAS

by · The Cerbat Gem

Candriam S.C.A. lowered its holdings in Exact Sciences Corporation (NASDAQ:EXAS – Free Report) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 345,399 shares of the medical research company’s stock after selling 11,576 shares during the period. Candriam S.C.A. owned approximately 0.18% of Exact Sciences worth $18,355,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Larson Financial Group LLC raised its holdings in Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 589 shares during the period. National Pension Service grew its position in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 292 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of Exact Sciences during the 1st quarter valued at $30,000. True Wealth Design LLC raised its stake in shares of Exact Sciences by 951.8% during the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 533 shares during the period. Finally, Banque Cantonale Vaudoise purchased a new stake in Exact Sciences during the 1st quarter worth about $34,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Cowen reiterated a “buy” rating on shares of Exact Sciences in a research report on Tuesday, November 4th. Benchmark upped their target price on shares of Exact Sciences from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Barclays raised their price target on shares of Exact Sciences from $65.00 to $77.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Piper Sandler boosted their price target on shares of Exact Sciences from $70.00 to $80.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Zacks Research upgraded Exact Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $74.06.

Read Our Latest Stock Analysis on Exact Sciences

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $67.75 on Friday. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $72.81. The company has a market capitalization of $12.84 billion, a price-to-earnings ratio of -12.48, a PEG ratio of 5.56 and a beta of 1.34. The business has a 50 day moving average of $59.57 and a 200 day moving average of $54.03. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56.

Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.Exact Sciences’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the transaction, the executive vice president owned 22,368 shares in the company, valued at approximately $1,567,549.44. This represents a 11.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the sale, the director directly owned 57,962 shares in the company, valued at $3,477,720. This represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.20% of the stock is currently owned by insiders.

Exact Sciences Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS – Free Report).